377 related articles for article (PubMed ID: 19349354)
1. Global levels of histone modifications predict prognosis in different cancers.
Seligson DB; Horvath S; McBrian MA; Mah V; Yu H; Tze S; Wang Q; Chia D; Goodglick L; Kurdistani SK
Am J Pathol; 2009 May; 174(5):1619-28. PubMed ID: 19349354
[TBL] [Abstract][Full Text] [Related]
2. Global histone modification patterns predict risk of prostate cancer recurrence.
Seligson DB; Horvath S; Shi T; Yu H; Tze S; Grunstein M; Kurdistani SK
Nature; 2005 Jun; 435(7046):1262-6. PubMed ID: 15988529
[TBL] [Abstract][Full Text] [Related]
3. Histone modifications in cancer biology and prognosis.
Kurdistani SK
Prog Drug Res; 2011; 67():91-106. PubMed ID: 21141726
[TBL] [Abstract][Full Text] [Related]
4. Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704.
Manuyakorn A; Paulus R; Farrell J; Dawson NA; Tze S; Cheung-Lau G; Hines OJ; Reber H; Seligson DB; Horvath S; Kurdistani SK; Guha C; Dawson DW
J Clin Oncol; 2010 Mar; 28(8):1358-65. PubMed ID: 20142597
[TBL] [Abstract][Full Text] [Related]
5. Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development.
Bianco-Miotto T; Chiam K; Buchanan G; Jindal S; Day TK; Thomas M; Pickering MA; O'Loughlin MA; Ryan NK; Raymond WA; Horvath LG; Kench JG; Stricker PD; Marshall VR; Sutherland RL; Henshall SM; Gerald WL; Scher HI; Risbridger GP; Clements JA; Butler LM; Tilley WD; Horsfall DJ; Ricciardelli C;
Cancer Epidemiol Biomarkers Prev; 2010 Oct; 19(10):2611-22. PubMed ID: 20841388
[TBL] [Abstract][Full Text] [Related]
6. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation.
Kondo Y; Shen L; Cheng AS; Ahmed S; Boumber Y; Charo C; Yamochi T; Urano T; Furukawa K; Kwabi-Addo B; Gold DL; Sekido Y; Huang TH; Issa JP
Nat Genet; 2008 Jun; 40(6):741-50. PubMed ID: 18488029
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic modifications of RASSF1A gene through chromatin remodeling in prostate cancer.
Kawamoto K; Okino ST; Place RF; Urakami S; Hirata H; Kikuno N; Kawakami T; Tanaka Y; Pookot D; Chen Z; Majid S; Enokida H; Nakagawa M; Dahiya R
Clin Cancer Res; 2007 May; 13(9):2541-8. PubMed ID: 17473182
[TBL] [Abstract][Full Text] [Related]
8. The global histone modification pattern correlates with overall survival in metachronous liver metastasis of colorectal cancer.
Tamagawa H; Oshima T; Shiozawa M; Morinaga S; Nakamura Y; Yoshihara M; Sakuma Y; Kameda Y; Akaike M; Masuda M; Imada T; Miyagi Y
Oncol Rep; 2012 Mar; 27(3):637-42. PubMed ID: 22076537
[TBL] [Abstract][Full Text] [Related]
9. Global levels of histone modifications predict prostate cancer recurrence.
Ellinger J; Kahl P; von der Gathen J; Rogenhofer S; Heukamp LC; Gütgemann I; Walter B; Hofstädter F; Büttner R; Müller SC; Bastian PJ; von Ruecker A
Prostate; 2010 Jan; 70(1):61-9. PubMed ID: 19739128
[TBL] [Abstract][Full Text] [Related]
10. High expression of trimethylated histone H3 at lysine 27 predicts better prognosis in non-small cell lung cancer.
Chen X; Song N; Matsumoto K; Nanashima A; Nagayasu T; Hayashi T; Ying M; Endo D; Wu Z; Koji T
Int J Oncol; 2013 Nov; 43(5):1467-80. PubMed ID: 23969945
[TBL] [Abstract][Full Text] [Related]
11. Global histone acetylation levels: prognostic relevance in patients with renal cell carcinoma.
Mosashvilli D; Kahl P; Mertens C; Holzapfel S; Rogenhofer S; Hauser S; Büttner R; Von Ruecker A; Müller SC; Ellinger J
Cancer Sci; 2010 Dec; 101(12):2664-9. PubMed ID: 20825416
[TBL] [Abstract][Full Text] [Related]
12. Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome.
Elsheikh SE; Green AR; Rakha EA; Powe DG; Ahmed RA; Collins HM; Soria D; Garibaldi JM; Paish CE; Ammar AA; Grainge MJ; Ball GR; Abdelghany MK; Martinez-Pomares L; Heery DM; Ellis IO
Cancer Res; 2009 May; 69(9):3802-9. PubMed ID: 19366799
[TBL] [Abstract][Full Text] [Related]
13. Association of global levels of histone modifications with recurrence-free survival in stage IIB and III esophageal squamous cell carcinomas.
I H; Ko E; Kim Y; Cho EY; Han J; Park J; Kim K; Kim DH; Shim YM
Cancer Epidemiol Biomarkers Prev; 2010 Feb; 19(2):566-73. PubMed ID: 20142251
[TBL] [Abstract][Full Text] [Related]
14. Global histone modification of histone H3 in colorectal cancer and its precursor lesions.
Nakazawa T; Kondo T; Ma D; Niu D; Mochizuki K; Kawasaki T; Yamane T; Iino H; Fujii H; Katoh R
Hum Pathol; 2012 Jun; 43(6):834-42. PubMed ID: 21917293
[TBL] [Abstract][Full Text] [Related]
15. Dysregulation of Sirtuin 2 (SIRT2) and histone H3K18 acetylation pathways associates with adverse prostate cancer outcomes.
Damodaran S; Damaschke N; Gawdzik J; Yang B; Shi C; Allen GO; Huang W; Denu J; Jarrard D
BMC Cancer; 2017 Dec; 17(1):874. PubMed ID: 29262808
[TBL] [Abstract][Full Text] [Related]
16. Sulforaphane modulates telomerase activity via epigenetic regulation in prostate cancer cell lines.
Abbas A; Hall JA; Patterson WL; Ho E; Hsu A; Al-Mulla F; Georgel PT
Biochem Cell Biol; 2016 Feb; 94(1):71-81. PubMed ID: 26458818
[TBL] [Abstract][Full Text] [Related]
17. Promoter- and cell-specific epigenetic regulation of CD44, Cyclin D2, GLIPR1 and PTEN by methyl-CpG binding proteins and histone modifications.
Müller I; Wischnewski F; Pantel K; Schwarzenbach H
BMC Cancer; 2010 Jun; 10():297. PubMed ID: 20565761
[TBL] [Abstract][Full Text] [Related]
18. Loss of special AT-rich binding protein 1 expression is a marker of poor survival in lung cancer.
Selinger CI; Cooper WA; Al-Sohaily S; Mladenova DN; Pangon L; Kennedy CW; McCaughan BC; Stirzaker C; Kohonen-Corish MR
J Thorac Oncol; 2011 Jul; 6(7):1179-89. PubMed ID: 21597389
[TBL] [Abstract][Full Text] [Related]
19. Global histone modifications predict prognosis of resected non small-cell lung cancer.
Barlési F; Giaccone G; Gallegos-Ruiz MI; Loundou A; Span SW; Lefesvre P; Kruyt FA; Rodriguez JA
J Clin Oncol; 2007 Oct; 25(28):4358-64. PubMed ID: 17906200
[TBL] [Abstract][Full Text] [Related]
20. Promoter histone H3 lysine 9 di-methylation is associated with DNA methylation and aberrant expression of p16 in gastric cancer cells.
Meng CF; Zhu XJ; Peng G; Dai DQ
Oncol Rep; 2009 Nov; 22(5):1221-7. PubMed ID: 19787243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
